Vitiligo Treatment
Vitiligo Treatment

Vitiligo Treatment Comprehensive Study by Type (Topical Treatment, Light Therapy, Surgical Procedures, Others), Application (Hospitals, Aesthetic Clinics, Others), Drugs (ARN-4079, ATI-50001, AX-1602, Ruxolitinib Phosphate, VLRX-001, Others), Drug Class (Calcineurin Inhibitors, Corticosteroids, Psoralens) Players and Region - Global Market Outlook to 2026

Vitiligo Treatment Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Jan 2021 Edition 209 Pages 211 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Global Vitiligo Treatment Market Overview:
Vitiligo is a skin disease that prevents through a long-term period, also patches the skin to lose their colour. The skin patches that are affected by the disease Vitiligo become white. This kind of disease happens because of melanocytes within the skin die off. Moreover, skin pigmentation, melanin, due to which skin has its colour, protection from sun UV rays this all happens because of melanocyte cells. Hence the deficiency of this pigment can create diseases like this. Therefore, the growing per capita healthcare expenditure, improving healthcare infrastructure in developing countries, growing disease awareness and expected approval of Vitiligo treatment are some of the driving forces for the growth of this market. In addition to that, the key players are focusing on adopting collaboration and acquisition strategies.

Growth Drivers
  • Rising Demand for Innovative and Modern Treatment Options for Vitiligo
  • Increasing Number of Vitiligo Patients to Favour Growth in the Asia Pacific

Market Trends
  • Adopting Collaboration and Acquisition Strategies to Develop and Commercialize Novel Vitiligo Treatment Drugs in Order to Expand their Product Portfolio

Roadblocks
  • Shortage of Dermatologists and Available Treatments Having a Longer Duration of Times
  • Reduction in the Diagnosis Rate may Hamper the Vitiligo Drug Market Growth

Opportunities
  • Increasing Research and Development Activities Related to Vitiligo Treatment is Expected to Facilitate the Growth of the Market over the Forecast Period

Challenges
  • Lack of Awareness Regarding the Available Vitiligo Treatment
  • Counterfeit of these Vitiligo Treatment


Competitive Landscape:
The global market is highly competitive and consists of a limited number of providers who compete with each other. The intense competition, changing consumer spending patterns, demographic trends, and frequent changes in consumer preferences pose significant opportunities for market growth.
Some of the key players profiled in the report are Boston Pharmaceuticals (United States), Incyte (United States), Astellas Pharma (Japan), Bausch Health (Canada), Baxter (United States), Pfizer (United States), STRATA Skin Sciences (United States), Dr. Reddy's Laboratories (India), Bristol-Myers Squibb (United States), Celgene (United States) and Clinuvel Pharmaceuticals (Australia). Analyst at AMA Research see United States Players to retain maximum share of Global Vitiligo Treatment market by 2026. Considering Market by Drugs, the sub-segment i.e. ARN-4079 will boost the Vitiligo Treatment market. Considering Market by Drug Class, the sub-segment i.e. Calcineurin Inhibitors will boost the Vitiligo Treatment market.

Latest Market Insights:
In October 2018, Boston Pharmaceutical entered into a licensing agreement with GlaxoSmithKline for the development and commercialization of phase 1 drug products for the treatment of vitiligo.

In 2018, Boston Pharmaceutical expanded its product pipeline by adding a topical formulation called GSK3183475 from GlaksoSmith Kline, a small molecule inhibitor used in the treatment of vitiligo and psoriasis, currently in phase 1 clinical trial.

Available Customization:
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be provided prior to purchase

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Vitiligo Treatment market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Vitiligo Treatment market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Vitiligo Drug and Surgical Instruments Manufactures, Potential Investors, Government Bodies and Associations, Up and Down Stream Vendors, Private Research Organizations, Suppliers and Distributors and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.
Report Objectives / Segmentation Covered
By Type
  • Topical Treatment
  • Light Therapy
  • Surgical Procedures
  • Others
By Application
  • Hospitals
  • Aesthetic Clinics
  • Others
By Drugs
  • ARN-4079
  • ATI-50001
  • AX-1602
  • Ruxolitinib Phosphate
  • VLRX-001
  • Others

By Drug Class
  • Calcineurin Inhibitors
  • Corticosteroids
  • Psoralens

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Demand for Innovative and Modern Treatment Options for Vitiligo
      • 3.2.2. Increasing Number of Vitiligo Patients to Favour Growth in the Asia Pacific
    • 3.3. Market Challenges
      • 3.3.1. Lack of Awareness Regarding the Available Vitiligo Treatment
      • 3.3.2. Counterfeit of these Vitiligo Treatment
    • 3.4. Market Trends
      • 3.4.1. Adopting Collaboration and Acquisition Strategies to Develop and Commercialize Novel Vitiligo Treatment Drugs in Order to Expand their Product Portfolio
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Vitiligo Treatment, by Type, Application, Drugs, Drug Class and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Vitiligo Treatment (Value)
      • 5.2.1. Global Vitiligo Treatment by: Type (Value)
        • 5.2.1.1. Topical Treatment
        • 5.2.1.2. Light Therapy
        • 5.2.1.3. Surgical Procedures
        • 5.2.1.4. Others
      • 5.2.2. Global Vitiligo Treatment by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Aesthetic Clinics
        • 5.2.2.3. Others
      • 5.2.3. Global Vitiligo Treatment by: Drugs (Value)
        • 5.2.3.1. ARN-4079
        • 5.2.3.2. ATI-50001
        • 5.2.3.3. AX-1602
        • 5.2.3.4. Ruxolitinib Phosphate
        • 5.2.3.5. VLRX-001
        • 5.2.3.6. Others
      • 5.2.4. Global Vitiligo Treatment by: Drug Class (Value)
        • 5.2.4.1. Calcineurin Inhibitors
        • 5.2.4.2. Corticosteroids
        • 5.2.4.3. Psoralens
      • 5.2.5. Global Vitiligo Treatment Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Vitiligo Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Boston Pharmaceuticals (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Incyte (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Astellas Pharma (Japan)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Bausch Health (Canada)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Baxter (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Pfizer (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. STRATA Skin Sciences (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Dr. Reddy's Laboratories (India)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Bristol-Myers Squibb (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Celgene (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Clinuvel Pharmaceuticals (Australia)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Vitiligo Treatment Sale, by Type, Application, Drugs, Drug Class and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Vitiligo Treatment (Value)
      • 7.2.1. Global Vitiligo Treatment by: Type (Value)
        • 7.2.1.1. Topical Treatment
        • 7.2.1.2. Light Therapy
        • 7.2.1.3. Surgical Procedures
        • 7.2.1.4. Others
      • 7.2.2. Global Vitiligo Treatment by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Aesthetic Clinics
        • 7.2.2.3. Others
      • 7.2.3. Global Vitiligo Treatment by: Drugs (Value)
        • 7.2.3.1. ARN-4079
        • 7.2.3.2. ATI-50001
        • 7.2.3.3. AX-1602
        • 7.2.3.4. Ruxolitinib Phosphate
        • 7.2.3.5. VLRX-001
        • 7.2.3.6. Others
      • 7.2.4. Global Vitiligo Treatment by: Drug Class (Value)
        • 7.2.4.1. Calcineurin Inhibitors
        • 7.2.4.2. Corticosteroids
        • 7.2.4.3. Psoralens
      • 7.2.5. Global Vitiligo Treatment Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Vitiligo Treatment: by Type(USD Million)
  • Table 2. Vitiligo Treatment Topical Treatment , by Region USD Million (2015-2020)
  • Table 3. Vitiligo Treatment Light Therapy , by Region USD Million (2015-2020)
  • Table 4. Vitiligo Treatment Surgical Procedures , by Region USD Million (2015-2020)
  • Table 5. Vitiligo Treatment Others , by Region USD Million (2015-2020)
  • Table 6. Vitiligo Treatment: by Application(USD Million)
  • Table 7. Vitiligo Treatment Hospitals , by Region USD Million (2015-2020)
  • Table 8. Vitiligo Treatment Aesthetic Clinics , by Region USD Million (2015-2020)
  • Table 9. Vitiligo Treatment Others , by Region USD Million (2015-2020)
  • Table 10. Vitiligo Treatment: by Drugs(USD Million)
  • Table 11. Vitiligo Treatment ARN-4079 , by Region USD Million (2015-2020)
  • Table 12. Vitiligo Treatment ATI-50001 , by Region USD Million (2015-2020)
  • Table 13. Vitiligo Treatment AX-1602 , by Region USD Million (2015-2020)
  • Table 14. Vitiligo Treatment Ruxolitinib Phosphate , by Region USD Million (2015-2020)
  • Table 15. Vitiligo Treatment VLRX-001 , by Region USD Million (2015-2020)
  • Table 16. Vitiligo Treatment Others , by Region USD Million (2015-2020)
  • Table 17. Vitiligo Treatment: by Drug Class(USD Million)
  • Table 18. Vitiligo Treatment Calcineurin Inhibitors , by Region USD Million (2015-2020)
  • Table 19. Vitiligo Treatment Corticosteroids , by Region USD Million (2015-2020)
  • Table 20. Vitiligo Treatment Psoralens , by Region USD Million (2015-2020)
  • Table 21. South America Vitiligo Treatment, by Country USD Million (2015-2020)
  • Table 22. South America Vitiligo Treatment, by Type USD Million (2015-2020)
  • Table 23. South America Vitiligo Treatment, by Application USD Million (2015-2020)
  • Table 24. South America Vitiligo Treatment, by Drugs USD Million (2015-2020)
  • Table 25. South America Vitiligo Treatment, by Drug Class USD Million (2015-2020)
  • Table 26. Brazil Vitiligo Treatment, by Type USD Million (2015-2020)
  • Table 27. Brazil Vitiligo Treatment, by Application USD Million (2015-2020)
  • Table 28. Brazil Vitiligo Treatment, by Drugs USD Million (2015-2020)
  • Table 29. Brazil Vitiligo Treatment, by Drug Class USD Million (2015-2020)
  • Table 30. Argentina Vitiligo Treatment, by Type USD Million (2015-2020)
  • Table 31. Argentina Vitiligo Treatment, by Application USD Million (2015-2020)
  • Table 32. Argentina Vitiligo Treatment, by Drugs USD Million (2015-2020)
  • Table 33. Argentina Vitiligo Treatment, by Drug Class USD Million (2015-2020)
  • Table 34. Rest of South America Vitiligo Treatment, by Type USD Million (2015-2020)
  • Table 35. Rest of South America Vitiligo Treatment, by Application USD Million (2015-2020)
  • Table 36. Rest of South America Vitiligo Treatment, by Drugs USD Million (2015-2020)
  • Table 37. Rest of South America Vitiligo Treatment, by Drug Class USD Million (2015-2020)
  • Table 38. Asia Pacific Vitiligo Treatment, by Country USD Million (2015-2020)
  • Table 39. Asia Pacific Vitiligo Treatment, by Type USD Million (2015-2020)
  • Table 40. Asia Pacific Vitiligo Treatment, by Application USD Million (2015-2020)
  • Table 41. Asia Pacific Vitiligo Treatment, by Drugs USD Million (2015-2020)
  • Table 42. Asia Pacific Vitiligo Treatment, by Drug Class USD Million (2015-2020)
  • Table 43. China Vitiligo Treatment, by Type USD Million (2015-2020)
  • Table 44. China Vitiligo Treatment, by Application USD Million (2015-2020)
  • Table 45. China Vitiligo Treatment, by Drugs USD Million (2015-2020)
  • Table 46. China Vitiligo Treatment, by Drug Class USD Million (2015-2020)
  • Table 47. Japan Vitiligo Treatment, by Type USD Million (2015-2020)
  • Table 48. Japan Vitiligo Treatment, by Application USD Million (2015-2020)
  • Table 49. Japan Vitiligo Treatment, by Drugs USD Million (2015-2020)
  • Table 50. Japan Vitiligo Treatment, by Drug Class USD Million (2015-2020)
  • Table 51. India Vitiligo Treatment, by Type USD Million (2015-2020)
  • Table 52. India Vitiligo Treatment, by Application USD Million (2015-2020)
  • Table 53. India Vitiligo Treatment, by Drugs USD Million (2015-2020)
  • Table 54. India Vitiligo Treatment, by Drug Class USD Million (2015-2020)
  • Table 55. South Korea Vitiligo Treatment, by Type USD Million (2015-2020)
  • Table 56. South Korea Vitiligo Treatment, by Application USD Million (2015-2020)
  • Table 57. South Korea Vitiligo Treatment, by Drugs USD Million (2015-2020)
  • Table 58. South Korea Vitiligo Treatment, by Drug Class USD Million (2015-2020)
  • Table 59. Taiwan Vitiligo Treatment, by Type USD Million (2015-2020)
  • Table 60. Taiwan Vitiligo Treatment, by Application USD Million (2015-2020)
  • Table 61. Taiwan Vitiligo Treatment, by Drugs USD Million (2015-2020)
  • Table 62. Taiwan Vitiligo Treatment, by Drug Class USD Million (2015-2020)
  • Table 63. Australia Vitiligo Treatment, by Type USD Million (2015-2020)
  • Table 64. Australia Vitiligo Treatment, by Application USD Million (2015-2020)
  • Table 65. Australia Vitiligo Treatment, by Drugs USD Million (2015-2020)
  • Table 66. Australia Vitiligo Treatment, by Drug Class USD Million (2015-2020)
  • Table 67. Rest of Asia-Pacific Vitiligo Treatment, by Type USD Million (2015-2020)
  • Table 68. Rest of Asia-Pacific Vitiligo Treatment, by Application USD Million (2015-2020)
  • Table 69. Rest of Asia-Pacific Vitiligo Treatment, by Drugs USD Million (2015-2020)
  • Table 70. Rest of Asia-Pacific Vitiligo Treatment, by Drug Class USD Million (2015-2020)
  • Table 71. Europe Vitiligo Treatment, by Country USD Million (2015-2020)
  • Table 72. Europe Vitiligo Treatment, by Type USD Million (2015-2020)
  • Table 73. Europe Vitiligo Treatment, by Application USD Million (2015-2020)
  • Table 74. Europe Vitiligo Treatment, by Drugs USD Million (2015-2020)
  • Table 75. Europe Vitiligo Treatment, by Drug Class USD Million (2015-2020)
  • Table 76. Germany Vitiligo Treatment, by Type USD Million (2015-2020)
  • Table 77. Germany Vitiligo Treatment, by Application USD Million (2015-2020)
  • Table 78. Germany Vitiligo Treatment, by Drugs USD Million (2015-2020)
  • Table 79. Germany Vitiligo Treatment, by Drug Class USD Million (2015-2020)
  • Table 80. France Vitiligo Treatment, by Type USD Million (2015-2020)
  • Table 81. France Vitiligo Treatment, by Application USD Million (2015-2020)
  • Table 82. France Vitiligo Treatment, by Drugs USD Million (2015-2020)
  • Table 83. France Vitiligo Treatment, by Drug Class USD Million (2015-2020)
  • Table 84. Italy Vitiligo Treatment, by Type USD Million (2015-2020)
  • Table 85. Italy Vitiligo Treatment, by Application USD Million (2015-2020)
  • Table 86. Italy Vitiligo Treatment, by Drugs USD Million (2015-2020)
  • Table 87. Italy Vitiligo Treatment, by Drug Class USD Million (2015-2020)
  • Table 88. United Kingdom Vitiligo Treatment, by Type USD Million (2015-2020)
  • Table 89. United Kingdom Vitiligo Treatment, by Application USD Million (2015-2020)
  • Table 90. United Kingdom Vitiligo Treatment, by Drugs USD Million (2015-2020)
  • Table 91. United Kingdom Vitiligo Treatment, by Drug Class USD Million (2015-2020)
  • Table 92. Netherlands Vitiligo Treatment, by Type USD Million (2015-2020)
  • Table 93. Netherlands Vitiligo Treatment, by Application USD Million (2015-2020)
  • Table 94. Netherlands Vitiligo Treatment, by Drugs USD Million (2015-2020)
  • Table 95. Netherlands Vitiligo Treatment, by Drug Class USD Million (2015-2020)
  • Table 96. Rest of Europe Vitiligo Treatment, by Type USD Million (2015-2020)
  • Table 97. Rest of Europe Vitiligo Treatment, by Application USD Million (2015-2020)
  • Table 98. Rest of Europe Vitiligo Treatment, by Drugs USD Million (2015-2020)
  • Table 99. Rest of Europe Vitiligo Treatment, by Drug Class USD Million (2015-2020)
  • Table 100. MEA Vitiligo Treatment, by Country USD Million (2015-2020)
  • Table 101. MEA Vitiligo Treatment, by Type USD Million (2015-2020)
  • Table 102. MEA Vitiligo Treatment, by Application USD Million (2015-2020)
  • Table 103. MEA Vitiligo Treatment, by Drugs USD Million (2015-2020)
  • Table 104. MEA Vitiligo Treatment, by Drug Class USD Million (2015-2020)
  • Table 105. Middle East Vitiligo Treatment, by Type USD Million (2015-2020)
  • Table 106. Middle East Vitiligo Treatment, by Application USD Million (2015-2020)
  • Table 107. Middle East Vitiligo Treatment, by Drugs USD Million (2015-2020)
  • Table 108. Middle East Vitiligo Treatment, by Drug Class USD Million (2015-2020)
  • Table 109. Africa Vitiligo Treatment, by Type USD Million (2015-2020)
  • Table 110. Africa Vitiligo Treatment, by Application USD Million (2015-2020)
  • Table 111. Africa Vitiligo Treatment, by Drugs USD Million (2015-2020)
  • Table 112. Africa Vitiligo Treatment, by Drug Class USD Million (2015-2020)
  • Table 113. North America Vitiligo Treatment, by Country USD Million (2015-2020)
  • Table 114. North America Vitiligo Treatment, by Type USD Million (2015-2020)
  • Table 115. North America Vitiligo Treatment, by Application USD Million (2015-2020)
  • Table 116. North America Vitiligo Treatment, by Drugs USD Million (2015-2020)
  • Table 117. North America Vitiligo Treatment, by Drug Class USD Million (2015-2020)
  • Table 118. United States Vitiligo Treatment, by Type USD Million (2015-2020)
  • Table 119. United States Vitiligo Treatment, by Application USD Million (2015-2020)
  • Table 120. United States Vitiligo Treatment, by Drugs USD Million (2015-2020)
  • Table 121. United States Vitiligo Treatment, by Drug Class USD Million (2015-2020)
  • Table 122. Canada Vitiligo Treatment, by Type USD Million (2015-2020)
  • Table 123. Canada Vitiligo Treatment, by Application USD Million (2015-2020)
  • Table 124. Canada Vitiligo Treatment, by Drugs USD Million (2015-2020)
  • Table 125. Canada Vitiligo Treatment, by Drug Class USD Million (2015-2020)
  • Table 126. Mexico Vitiligo Treatment, by Type USD Million (2015-2020)
  • Table 127. Mexico Vitiligo Treatment, by Application USD Million (2015-2020)
  • Table 128. Mexico Vitiligo Treatment, by Drugs USD Million (2015-2020)
  • Table 129. Mexico Vitiligo Treatment, by Drug Class USD Million (2015-2020)
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Vitiligo Treatment: by Type(USD Million)
  • Table 142. Vitiligo Treatment Topical Treatment , by Region USD Million (2021-2026)
  • Table 143. Vitiligo Treatment Light Therapy , by Region USD Million (2021-2026)
  • Table 144. Vitiligo Treatment Surgical Procedures , by Region USD Million (2021-2026)
  • Table 145. Vitiligo Treatment Others , by Region USD Million (2021-2026)
  • Table 146. Vitiligo Treatment: by Application(USD Million)
  • Table 147. Vitiligo Treatment Hospitals , by Region USD Million (2021-2026)
  • Table 148. Vitiligo Treatment Aesthetic Clinics , by Region USD Million (2021-2026)
  • Table 149. Vitiligo Treatment Others , by Region USD Million (2021-2026)
  • Table 150. Vitiligo Treatment: by Drugs(USD Million)
  • Table 151. Vitiligo Treatment ARN-4079 , by Region USD Million (2021-2026)
  • Table 152. Vitiligo Treatment ATI-50001 , by Region USD Million (2021-2026)
  • Table 153. Vitiligo Treatment AX-1602 , by Region USD Million (2021-2026)
  • Table 154. Vitiligo Treatment Ruxolitinib Phosphate , by Region USD Million (2021-2026)
  • Table 155. Vitiligo Treatment VLRX-001 , by Region USD Million (2021-2026)
  • Table 156. Vitiligo Treatment Others , by Region USD Million (2021-2026)
  • Table 157. Vitiligo Treatment: by Drug Class(USD Million)
  • Table 158. Vitiligo Treatment Calcineurin Inhibitors , by Region USD Million (2021-2026)
  • Table 159. Vitiligo Treatment Corticosteroids , by Region USD Million (2021-2026)
  • Table 160. Vitiligo Treatment Psoralens , by Region USD Million (2021-2026)
  • Table 161. South America Vitiligo Treatment, by Country USD Million (2021-2026)
  • Table 162. South America Vitiligo Treatment, by Type USD Million (2021-2026)
  • Table 163. South America Vitiligo Treatment, by Application USD Million (2021-2026)
  • Table 164. South America Vitiligo Treatment, by Drugs USD Million (2021-2026)
  • Table 165. South America Vitiligo Treatment, by Drug Class USD Million (2021-2026)
  • Table 166. Brazil Vitiligo Treatment, by Type USD Million (2021-2026)
  • Table 167. Brazil Vitiligo Treatment, by Application USD Million (2021-2026)
  • Table 168. Brazil Vitiligo Treatment, by Drugs USD Million (2021-2026)
  • Table 169. Brazil Vitiligo Treatment, by Drug Class USD Million (2021-2026)
  • Table 170. Argentina Vitiligo Treatment, by Type USD Million (2021-2026)
  • Table 171. Argentina Vitiligo Treatment, by Application USD Million (2021-2026)
  • Table 172. Argentina Vitiligo Treatment, by Drugs USD Million (2021-2026)
  • Table 173. Argentina Vitiligo Treatment, by Drug Class USD Million (2021-2026)
  • Table 174. Rest of South America Vitiligo Treatment, by Type USD Million (2021-2026)
  • Table 175. Rest of South America Vitiligo Treatment, by Application USD Million (2021-2026)
  • Table 176. Rest of South America Vitiligo Treatment, by Drugs USD Million (2021-2026)
  • Table 177. Rest of South America Vitiligo Treatment, by Drug Class USD Million (2021-2026)
  • Table 178. Asia Pacific Vitiligo Treatment, by Country USD Million (2021-2026)
  • Table 179. Asia Pacific Vitiligo Treatment, by Type USD Million (2021-2026)
  • Table 180. Asia Pacific Vitiligo Treatment, by Application USD Million (2021-2026)
  • Table 181. Asia Pacific Vitiligo Treatment, by Drugs USD Million (2021-2026)
  • Table 182. Asia Pacific Vitiligo Treatment, by Drug Class USD Million (2021-2026)
  • Table 183. China Vitiligo Treatment, by Type USD Million (2021-2026)
  • Table 184. China Vitiligo Treatment, by Application USD Million (2021-2026)
  • Table 185. China Vitiligo Treatment, by Drugs USD Million (2021-2026)
  • Table 186. China Vitiligo Treatment, by Drug Class USD Million (2021-2026)
  • Table 187. Japan Vitiligo Treatment, by Type USD Million (2021-2026)
  • Table 188. Japan Vitiligo Treatment, by Application USD Million (2021-2026)
  • Table 189. Japan Vitiligo Treatment, by Drugs USD Million (2021-2026)
  • Table 190. Japan Vitiligo Treatment, by Drug Class USD Million (2021-2026)
  • Table 191. India Vitiligo Treatment, by Type USD Million (2021-2026)
  • Table 192. India Vitiligo Treatment, by Application USD Million (2021-2026)
  • Table 193. India Vitiligo Treatment, by Drugs USD Million (2021-2026)
  • Table 194. India Vitiligo Treatment, by Drug Class USD Million (2021-2026)
  • Table 195. South Korea Vitiligo Treatment, by Type USD Million (2021-2026)
  • Table 196. South Korea Vitiligo Treatment, by Application USD Million (2021-2026)
  • Table 197. South Korea Vitiligo Treatment, by Drugs USD Million (2021-2026)
  • Table 198. South Korea Vitiligo Treatment, by Drug Class USD Million (2021-2026)
  • Table 199. Taiwan Vitiligo Treatment, by Type USD Million (2021-2026)
  • Table 200. Taiwan Vitiligo Treatment, by Application USD Million (2021-2026)
  • Table 201. Taiwan Vitiligo Treatment, by Drugs USD Million (2021-2026)
  • Table 202. Taiwan Vitiligo Treatment, by Drug Class USD Million (2021-2026)
  • Table 203. Australia Vitiligo Treatment, by Type USD Million (2021-2026)
  • Table 204. Australia Vitiligo Treatment, by Application USD Million (2021-2026)
  • Table 205. Australia Vitiligo Treatment, by Drugs USD Million (2021-2026)
  • Table 206. Australia Vitiligo Treatment, by Drug Class USD Million (2021-2026)
  • Table 207. Rest of Asia-Pacific Vitiligo Treatment, by Type USD Million (2021-2026)
  • Table 208. Rest of Asia-Pacific Vitiligo Treatment, by Application USD Million (2021-2026)
  • Table 209. Rest of Asia-Pacific Vitiligo Treatment, by Drugs USD Million (2021-2026)
  • Table 210. Rest of Asia-Pacific Vitiligo Treatment, by Drug Class USD Million (2021-2026)
  • Table 211. Europe Vitiligo Treatment, by Country USD Million (2021-2026)
  • Table 212. Europe Vitiligo Treatment, by Type USD Million (2021-2026)
  • Table 213. Europe Vitiligo Treatment, by Application USD Million (2021-2026)
  • Table 214. Europe Vitiligo Treatment, by Drugs USD Million (2021-2026)
  • Table 215. Europe Vitiligo Treatment, by Drug Class USD Million (2021-2026)
  • Table 216. Germany Vitiligo Treatment, by Type USD Million (2021-2026)
  • Table 217. Germany Vitiligo Treatment, by Application USD Million (2021-2026)
  • Table 218. Germany Vitiligo Treatment, by Drugs USD Million (2021-2026)
  • Table 219. Germany Vitiligo Treatment, by Drug Class USD Million (2021-2026)
  • Table 220. France Vitiligo Treatment, by Type USD Million (2021-2026)
  • Table 221. France Vitiligo Treatment, by Application USD Million (2021-2026)
  • Table 222. France Vitiligo Treatment, by Drugs USD Million (2021-2026)
  • Table 223. France Vitiligo Treatment, by Drug Class USD Million (2021-2026)
  • Table 224. Italy Vitiligo Treatment, by Type USD Million (2021-2026)
  • Table 225. Italy Vitiligo Treatment, by Application USD Million (2021-2026)
  • Table 226. Italy Vitiligo Treatment, by Drugs USD Million (2021-2026)
  • Table 227. Italy Vitiligo Treatment, by Drug Class USD Million (2021-2026)
  • Table 228. United Kingdom Vitiligo Treatment, by Type USD Million (2021-2026)
  • Table 229. United Kingdom Vitiligo Treatment, by Application USD Million (2021-2026)
  • Table 230. United Kingdom Vitiligo Treatment, by Drugs USD Million (2021-2026)
  • Table 231. United Kingdom Vitiligo Treatment, by Drug Class USD Million (2021-2026)
  • Table 232. Netherlands Vitiligo Treatment, by Type USD Million (2021-2026)
  • Table 233. Netherlands Vitiligo Treatment, by Application USD Million (2021-2026)
  • Table 234. Netherlands Vitiligo Treatment, by Drugs USD Million (2021-2026)
  • Table 235. Netherlands Vitiligo Treatment, by Drug Class USD Million (2021-2026)
  • Table 236. Rest of Europe Vitiligo Treatment, by Type USD Million (2021-2026)
  • Table 237. Rest of Europe Vitiligo Treatment, by Application USD Million (2021-2026)
  • Table 238. Rest of Europe Vitiligo Treatment, by Drugs USD Million (2021-2026)
  • Table 239. Rest of Europe Vitiligo Treatment, by Drug Class USD Million (2021-2026)
  • Table 240. MEA Vitiligo Treatment, by Country USD Million (2021-2026)
  • Table 241. MEA Vitiligo Treatment, by Type USD Million (2021-2026)
  • Table 242. MEA Vitiligo Treatment, by Application USD Million (2021-2026)
  • Table 243. MEA Vitiligo Treatment, by Drugs USD Million (2021-2026)
  • Table 244. MEA Vitiligo Treatment, by Drug Class USD Million (2021-2026)
  • Table 245. Middle East Vitiligo Treatment, by Type USD Million (2021-2026)
  • Table 246. Middle East Vitiligo Treatment, by Application USD Million (2021-2026)
  • Table 247. Middle East Vitiligo Treatment, by Drugs USD Million (2021-2026)
  • Table 248. Middle East Vitiligo Treatment, by Drug Class USD Million (2021-2026)
  • Table 249. Africa Vitiligo Treatment, by Type USD Million (2021-2026)
  • Table 250. Africa Vitiligo Treatment, by Application USD Million (2021-2026)
  • Table 251. Africa Vitiligo Treatment, by Drugs USD Million (2021-2026)
  • Table 252. Africa Vitiligo Treatment, by Drug Class USD Million (2021-2026)
  • Table 253. North America Vitiligo Treatment, by Country USD Million (2021-2026)
  • Table 254. North America Vitiligo Treatment, by Type USD Million (2021-2026)
  • Table 255. North America Vitiligo Treatment, by Application USD Million (2021-2026)
  • Table 256. North America Vitiligo Treatment, by Drugs USD Million (2021-2026)
  • Table 257. North America Vitiligo Treatment, by Drug Class USD Million (2021-2026)
  • Table 258. United States Vitiligo Treatment, by Type USD Million (2021-2026)
  • Table 259. United States Vitiligo Treatment, by Application USD Million (2021-2026)
  • Table 260. United States Vitiligo Treatment, by Drugs USD Million (2021-2026)
  • Table 261. United States Vitiligo Treatment, by Drug Class USD Million (2021-2026)
  • Table 262. Canada Vitiligo Treatment, by Type USD Million (2021-2026)
  • Table 263. Canada Vitiligo Treatment, by Application USD Million (2021-2026)
  • Table 264. Canada Vitiligo Treatment, by Drugs USD Million (2021-2026)
  • Table 265. Canada Vitiligo Treatment, by Drug Class USD Million (2021-2026)
  • Table 266. Mexico Vitiligo Treatment, by Type USD Million (2021-2026)
  • Table 267. Mexico Vitiligo Treatment, by Application USD Million (2021-2026)
  • Table 268. Mexico Vitiligo Treatment, by Drugs USD Million (2021-2026)
  • Table 269. Mexico Vitiligo Treatment, by Drug Class USD Million (2021-2026)
  • Table 270. Research Programs/Design for This Report
  • Table 271. Key Data Information from Secondary Sources
  • Table 272. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Vitiligo Treatment: by Type USD Million (2015-2020)
  • Figure 5. Global Vitiligo Treatment: by Application USD Million (2015-2020)
  • Figure 6. Global Vitiligo Treatment: by Drugs USD Million (2015-2020)
  • Figure 7. Global Vitiligo Treatment: by Drug Class USD Million (2015-2020)
  • Figure 8. South America Vitiligo Treatment Share (%), by Country
  • Figure 9. Asia Pacific Vitiligo Treatment Share (%), by Country
  • Figure 10. Europe Vitiligo Treatment Share (%), by Country
  • Figure 11. MEA Vitiligo Treatment Share (%), by Country
  • Figure 12. North America Vitiligo Treatment Share (%), by Country
  • Figure 13. Global Vitiligo Treatment share by Players 2020 (%)
  • Figure 14. Global Vitiligo Treatment share by Players (Top 3) 2020(%)
  • Figure 15. Global Vitiligo Treatment share by Players (Top 5) 2020(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Boston Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 18. Boston Pharmaceuticals (United States) Revenue: by Geography 2020
  • Figure 19. Incyte (United States) Revenue, Net Income and Gross profit
  • Figure 20. Incyte (United States) Revenue: by Geography 2020
  • Figure 21. Astellas Pharma (Japan) Revenue, Net Income and Gross profit
  • Figure 22. Astellas Pharma (Japan) Revenue: by Geography 2020
  • Figure 23. Bausch Health (Canada) Revenue, Net Income and Gross profit
  • Figure 24. Bausch Health (Canada) Revenue: by Geography 2020
  • Figure 25. Baxter (United States) Revenue, Net Income and Gross profit
  • Figure 26. Baxter (United States) Revenue: by Geography 2020
  • Figure 27. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 28. Pfizer (United States) Revenue: by Geography 2020
  • Figure 29. STRATA Skin Sciences (United States) Revenue, Net Income and Gross profit
  • Figure 30. STRATA Skin Sciences (United States) Revenue: by Geography 2020
  • Figure 31. Dr. Reddy's Laboratories (India) Revenue, Net Income and Gross profit
  • Figure 32. Dr. Reddy's Laboratories (India) Revenue: by Geography 2020
  • Figure 33. Bristol-Myers Squibb (United States) Revenue, Net Income and Gross profit
  • Figure 34. Bristol-Myers Squibb (United States) Revenue: by Geography 2020
  • Figure 35. Celgene (United States) Revenue, Net Income and Gross profit
  • Figure 36. Celgene (United States) Revenue: by Geography 2020
  • Figure 37. Clinuvel Pharmaceuticals (Australia) Revenue, Net Income and Gross profit
  • Figure 38. Clinuvel Pharmaceuticals (Australia) Revenue: by Geography 2020
  • Figure 39. Global Vitiligo Treatment: by Type USD Million (2021-2026)
  • Figure 40. Global Vitiligo Treatment: by Application USD Million (2021-2026)
  • Figure 41. Global Vitiligo Treatment: by Drugs USD Million (2021-2026)
  • Figure 42. Global Vitiligo Treatment: by Drug Class USD Million (2021-2026)
  • Figure 43. South America Vitiligo Treatment Share (%), by Country
  • Figure 44. Asia Pacific Vitiligo Treatment Share (%), by Country
  • Figure 45. Europe Vitiligo Treatment Share (%), by Country
  • Figure 46. MEA Vitiligo Treatment Share (%), by Country
  • Figure 47. North America Vitiligo Treatment Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Boston Pharmaceuticals (United States)
  • Incyte (United States)
  • Astellas Pharma (Japan)
  • Bausch Health (Canada)
  • Baxter (United States)
  • Pfizer (United States)
  • STRATA Skin Sciences (United States)
  • Dr. Reddy's Laboratories (India)
  • Bristol-Myers Squibb (United States)
  • Celgene (United States)
  • Clinuvel Pharmaceuticals (Australia)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation